November 7, 2008 — Extended therapy with buprenorphine-naloxone (Suboxone, Reckitt Benckiser Pharmaceuticals) substantially improves outcomes in opioid-addicted youth and might offer clinicians a new, ...
Cebranopadol is an investigational first-of-its kind dual NOP/MOP receptor (NMR) agonist which uses a novel approach of activating NOP and MOP ...
Few patients with opioid toxicity receive opioid agonist therapy (OAT), data suggest. In a retrospective study that examined about 21,000 hospital visits related to opioid use disorder (OUD) in ...
Sermorelin.com Unveils Telehealth Peptide Treatment for Lean Mass Preservation Sheridan, United States - February 27, ...
Please provide your email address to receive an email when new articles are posted on . Of 145,410 adults who began a GLP-1 drug, 76 developed thyroid cancer over a mean 3.9 years of follow-up. Risk ...
GLP-1 receptor agonists hold key market opportunities due to their effectiveness in diabetes and obesity management, expanding to cardiovascular and neurodegenerative disorders. Innovations like oral ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. SGLT2 inhibitors cut the risk for adverse CV outcomes ...
Following ablation for AF, GLP-1 agonist therapy is associated with decreased risk for AF recurrence in patients with type 2 diabetes. Glucagon-like peptide-1 receptor (GLP-1) agonist use is ...
Patients with diabetes being managed with GLP-1R agonists can expect a slight decrease in intraocular pressure. Glucagon-like peptide-1 receptor (GLP-1R) agonist therapy used for the treatment of ...
GLP-1 receptor agonists are linked to a 55% reduction in mortality risk in women with ovarian cancer, based on a retrospective cohort study. The study utilized data from the TriNetX Research Network, ...
Hosted on MSN
Study suggests lean muscle mass loss can be minimized during weight loss therapy using newer incretin obesity drugs
New research to be presented at the European Congress on Obesity (ECO 2025, Malaga, Spain, 11–14 May) shows that patients using GLP-1 or combined GLP-1 / GIP receptor agonist therapy for weight loss ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results